- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 307/81 - Radicals substituted by nitrogen atoms not forming part of a nitro radical
Patent holdings for IPC class C07D 307/81
Total number of patents in this class: 304
10-year publication summary
|
19
|
18
|
17
|
15
|
18
|
12
|
24
|
24
|
30
|
7
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Takeda Pharmaceutical Company Limited | 2712 |
17 |
| Sanofi | 4301 |
12 |
| Vanda Pharmaceuticals, Inc. | 386 |
10 |
| Tactogen Inc | 40 |
9 |
| Novartis AG | 10262 |
8 |
| Janssen Pharmaceutica N.V. | 3168 |
8 |
| BioCryst Pharmaceuticals, Inc. | 181 |
8 |
| Karyopharm Therapeutics Inc. | 144 |
7 |
| Akaal Pharma Pty Ltd. | 11 |
5 |
| io Therapeutics, Inc. | 125 |
5 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 873 |
5 |
| Scorpion Therapeutics, Inc. | 48 |
5 |
| Genentech, Inc. | 4104 |
4 |
| Les Laboratoires Servier | 496 |
4 |
| Vernalis (R&D) Limited | 123 |
4 |
| Ambient Photonics, Inc. | 17 |
4 |
| Merck Patent GmbH | 5728 |
3 |
| FUJIFILM Corporation | 30514 |
3 |
| Abbvie Inc. | 1836 |
3 |
| Antabio SAS | 23 |
3 |
| Other owners | 177 |